ReviewFrontiers in bioengineering and biotechnology2026
Harnessing biogenic nanoparticles for combating antibiotic resistance: green synthesis, mechanistic insights, and biotechnological applications.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Biogenic Metal Nanoparticles from Indian Flora as Programmable Bio-Interfaces: From Phytochemical Coronas to Precision Nanomedicine.International journal of molecular sciences · 2026Review
- Nano-enabled disruption of bacterial virulence and communication in plant pathosystems: emerging strategies for sustainable disease management.Frontiers in plant science · 2026Review
- Biogenic nanoparticles: overview of challenges in production, characterization and use.Frontiers in chemistry · 2026Review
- Nanomedicine against antimicrobial resistance: mechanistic insights and next-generation therapeutic potential.Frontiers in chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) continues to escalate worldwide, reducing the effectiveness of existing antibiotics and leading to an urgent need for alternative antimicrobial strategies. Biogenic nanoparticles (BNPs) are nanomaterials synthesized using plants, microorganisms, algae, or isolated biomolecules through biologically mediated processes. These green synthesis routes typically produce nanoparticles that are naturally capped with biological compounds such as phytochemicals, proteins, or polysaccharides, which can influence particle stability, surface chemistry, and biological interactions. The current review summarizes recent advances in the biosynthesis of BNPs, focusing on how biological metabolites regulate metal ion reduction, nucleation, growth, and stabilization, thereby shaping nanoparticle size, morphology, and antimicrobial behavior. BNPs including silver, gold, copper oxide, zinc oxide, iron oxide, titanium dioxide, and selenium have been widely investigated for antibacterial activity. Experimental studies indicate that these materials can act through multiple mechanisms, such as disruption of bacterial membranes, generation of reactive oxygen species, interference with metabolic processes, damage to DNA and proteins, inhibition of quorum sensing, and suppression of biofilm formation. Reported activity spans several WHO-priority and ESKAPE pathogens, largely based on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.